279 East Grand Avenue
South San Francisco
Tel: (650) 446-6630
Freenome is a high growth biotech company on a mission since 2014 to create tools that empower everyone to prevent, detect, and treat their disease.
To achieve this mission, Freenome is developing next-generation blood tests to detect cancer in its earliest, most treatable stages using our multiomics platform and machine learning techniques. Our first blood test will detect early-stage colorectal cancer and advanced adenomas.
We have raised more than $1.1B from leading investors including Andreessen Horowitz, Bain Capital, GV, Roche Venture Fund, Kaiser Permanente Ventures, American Cancer Society’s BrightEdge Ventures, Novartis, Verily, and more.
A ‘Freenomer’ is a mission-driven employee who is fueled by the opportunity to make a positive impact on patients' lives, who thrives in a culture of respect and cross collaboration, and whose work makes a significant impact on the company and their career.
What is Freenome? First and foremost, Freenome is a team. A cross-collaborative, mission-driven team developing next-generation blood tests for early cancer detection, so that we can find cancer when it’s most treatable.
38 articles with Freenome
FREENOME AND MERCK KGAA, DARMSTADT, GERMANY TO PRESENT DATA ON COMBINATION OF MULTIOMICS PROFILING AND COMPUTATIONAL MODELING AT AACR ANNUAL MEETING
Freenome announced its co-authorship of a study with Merck KGaA, Darmstadt Germany, a leading science and technology company.
Freenome Presents Research That Highlights The Significance Of Detecting Adenomas In Any Test That Screens For Colorectal Cancer
Freenome, a privately held biotech company, will present research at the American Association for Cancer Research Annual Meeting that measures the clinical impact of detecting precancerous adenomas for tests that screen for colorectal cancer, including multi-cancer early detection tests.
4/8/2022Onxeo, Amydis, eFFECTOR Therapeutics, Freenome, Urovant Sciences and others all added new guidance and perspectives to their C-suite this week.
Freenome, a privately held biotech company, today announced the initiation of Vallania, a clinical study for the refinement and further development of its multiomics platform to detect multiple cancers.
Freenome, a privately held biotech company, announced that Roche has made an investment of $290 million, bringing Freenome's total funding to more than $1.1 billion since the company was founded in 2014.
Roche’s investment is aimed at supporting the development of Freenome’s colorectal cancer detection technology.
Freenome Raises $300M in Series D Financing to Advance Multiomics Platform for Early Cancer Detection
Freenome, a privately held biotech company, announced a Series D funding of $300 million. This brings the company's total financing to over $800 million since the company was founded in 2014.
Freenome, a privately held biotech company, announced a partnership with Siemens Healthineers to collaborate in multiomics and radiomic breast cancer diagnostics to identify suitable markers for early breast cancer detection through blood to augment existing imaging technologies.
Freenome, a privately held biotech company, presented new research at the American College of Gastroenterology annual meeting that underscores their commitment to improving colorectal cancer screening.
The new CEO of Freenome has a talent for “making his own weather.” That’s a phrase he heard often growing up in Rapid City, South Dakota and, when applied to his life and career, comes down to assessing himself accurately and looking for opportunities to contribute.
Grail presents its first data from the interventional PATHFINDER trial of Galleri, its multi-cancer early detection blood test. Galleri is now available in the U.S. by prescription.
Freenome Presents Data Demonstrating the Importance of Clinical Test Performance and Screening Adherence on Colorectal Cancer Outcomes
Freenome presents findings from the CRC-MAPS™ model at the Digestive Disease Week (DDW) 2021 Annual Meeting
Freenome Presents Data Revealing Signatures of Immune Checkpoint Inhibitor Treatment Response Found to Be Common Across Kidney, Melanoma, and Lung Cancers
Freenome demonstrates potential for patient stratification and monitoring using its multiomics platform at the American Association for Cancer Research (AACR) Annual Meeting
Freenome’s Multiomics Blood Test Shows Promising Results in Detecting Colorectal Advanced Adenomas in a Prospective, Multi-Center Clinical Study
New results from the AI-EMERGE® study show Freenome’s multiomics blood test can detect colorectal advanced adenomas at 41% sensitivity and 90% specificity, which is comparable to or better than currently available non-invasive tests for colorectal cancer screening. This data, to be presented at ASCO-GI, build on previously reported data from a separate cohort that showed Freenome’s multiomics blood test can detect early-stage colorectal cancer
PREEMPT CRC™ Trial for Blood-Based Test to Detect Colon Cancer Has Expanded to Enroll Patients From Anywhere in the Continental U.S. During COVID-19 Pandemic
COVID-19 pandemic has caused significant decline in colonoscopies and underscores the value of less invasive screening options for colorectal cancer (CRC)
Freenome Closes $270 Million Series C Financing to Advance Novel Multiomics Blood Testing Platform for Early Cancer Detection
Proceeds will accelerate ongoing FDA registrational study of company’s first blood test for colorectal cancer screening and advance product pipeline
South San Francisco-based Freenome closed on an oversubscribed $270 million Series C financing.
Freenome Announces Initiation of the PREEMPT CRC Clinical Trial, a Registrational Study for the Early Detection and Prevention of Colorectal Cancer Using a Multiomics Blood Test
Freenome , a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine blood draw, announced several new developments: initiating its PREEMPT CRC clinical trial; adding Gary Reedy, CEO of the American
ADC Therapeutics to employ Freenome’s multiomics platform to identify biomarkers that correlate with clinical response to ADCT-402
Freenome Closes $160 Million Series B Financing to Advance Its Multiomics Blood Testing Platform for Early Cancer Detection
Proceeds Will Fund Pivotal Validation Study of Company’s Blood-based Test for the Screening of Colorectal Cancer